Zyla Life Sciences Costs and Expenses
Zyla Life Sciences reported Costs and Expenses of $33.50 million for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2020-05-14
- Zyla Life Sciences costs and expenses for the quarter ending 2020-03-31 was $33.50M.
- Zyla Life Sciences costs and expenses for the quarter ending 2019-09-30 was $30.05M, a 1.82% decline year-over-year.
- Zyla Life Sciences costs and expenses for the quarter ending 2019-06-30 was $37.57M.
- Zyla Life Sciences costs and expenses for the quarter ending 2018-12-31 was $18.34M, a 3.32% increase year-over-year.
- Zyla Life Sciences costs and expenses for fiscal 2018 was $87.94M.
| Period end | Costs and Expenses 1 month | Costs and Expenses 2 month | Costs and Expenses 3 month | Costs and Expenses 5 month | Costs and Expenses 6 month | Costs and Expenses 8 month | Costs and Expenses 9 month | Costs and Expenses 11 month | Costs and Expenses 12 month |
|---|---|---|---|---|---|---|---|---|---|
| 2020-03-31 | $33.50M 10-Q · filed 2020-05-14 | ||||||||
| 2019-12-31 | $115.16M 10-K · filed 2020-03-26 | ||||||||
| 2019-09-30 | $30.05M 10-Q · filed 2019-11-14 | $67.62M derived: sum of 2 quarters · filed 2019-11-14 | $91.12M 10-Q · filed 2019-11-14 | ||||||
| 2019-06-30 | $37.57M 10-Q · filed 2019-08-13 | $61.07M 10-Q · filed 2019-08-13 | |||||||
| 2019-03-31 | $23.49M 10-Q · filed 2020-05-14 | ||||||||
| 2019-01-31 | $9.90M 10-Q · filed 2020-05-14 | ||||||||
| 2018-12-31 | $18.34M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $48.95M derived: sum of 2 quarters · filed 2020-03-26 | $87.94M 10-K · filed 2020-03-26 | ||||||
| 2018-09-30 | $30.61M 10-Q · filed 2019-11-14 | $69.60M 10-Q · filed 2019-11-14 | |||||||
| 2017-12-31 | $17.75M 10-K · filed 2018-03-16 | $40.24M derived: sum of 2 quarters · filed 2018-03-16 | $68.24M derived: sum of 3 quarters · filed 2018-03-16 | $94.34M derived: sum of 4 quarters · filed 2018-03-16 | |||||
| 2017-09-30 | $22.48M 10-K · filed 2018-03-16 | $50.48M derived: sum of 2 quarters · filed 2018-03-16 | $76.58M derived: sum of 3 quarters · filed 2018-03-16 | $101.34M derived: sum of 4 quarters · filed 2018-03-16 | |||||
| 2017-06-30 | $28.00M 10-K · filed 2018-03-16 | $54.10M derived: sum of 2 quarters · filed 2018-03-16 | $78.85M derived: sum of 3 quarters · filed 2018-03-16 | $107.26M derived: sum of 4 quarters · filed 2018-03-16 | |||||
| 2017-03-31 | $26.10M 10-K · filed 2018-03-16 | $50.85M derived: sum of 2 quarters · filed 2018-03-16 | $79.26M derived: sum of 3 quarters · filed 2018-03-16 | $104.38M derived: sum of 4 quarters · filed 2018-03-16 | |||||
| 2016-12-31 | $24.76M 10-K · filed 2018-03-16 | $53.17M derived: sum of 2 quarters · filed 2018-03-16 | $78.28M derived: sum of 3 quarters · filed 2018-03-16 | $97.99M derived: sum of 4 quarters · filed 2018-03-16 | |||||
| 2016-09-30 | $28.41M 10-K · filed 2018-03-16 | $53.53M derived: sum of 2 quarters · filed 2018-03-16 | $73.23M derived: sum of 3 quarters · filed 2018-03-16 | ||||||
| 2016-06-30 | $25.12M 10-K · filed 2018-03-16 | $44.82M derived: sum of 2 quarters · filed 2018-03-16 | |||||||
| 2016-03-31 | $19.70M 10-K · filed 2018-03-16 |